In a move cheered by investors, Indian pharmaceuticals firm Matrix has persuaded its US-based parent Mylan Laboratories to purchase Aspen's stake in the Astrix joint venture.
NYSE-listed Mylan Laboratories to acquire 71.5% of IndiaÆs Matrix Laboratories for a maximum price of $736 million in deal in which private equity investors in Matrix Laboratories will take a stake in acquirer, Mylan.